Recruiting

PENG vs. Femoral

Sponsor:

Weill Medical College of Cornell University

Code:

NCT07073209

Conditions

Hip Fractures

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PENG Block Administration

Femoral Block Administration

Bupivacaine , epinephrine Dexamethasone

Study Details

Brief summary:

This study aims to compare the Pericapsular Nerve Group (PENG) block with femoral block for hip fracture pain. Participants presenting to the hospital with a diagnosis of hip fracture and consenting to analgesic block will receive either a PENG or femoral block. The choice of block will be dictated by a randomized monthly schedule, and all participants presenting during each four-week period will receive the designated block. A sub-group analysis will be performed to determine any difference in efficacy in participants with intracapsular versus extracapsular fractures.

Conditions

Hip Fractures

Study ID

NCT07073209

Start date

Jul 10, 2025

Status verified date

May, 2026

Completion date

Apr, 2027

Anticipated

Primary completion date

Mar, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Male or female ≥ 18 years of age.
2. ASA Classification 1-4
3. Documentation of a hip fracture diagnosis along with radiologic read indicating fracture location
4. Written, informed consent for analgesic peripheral block placement

Exclusion Criteria:

1. Altered mental status to the extent that it limits ability to report pain score
2. Patient or health care proxy refusal of analgesic nerve block
3. Allergy to study medications or contraindication to peripheral nerve block
4. Peri-prosthetic fracture
5. Any additional fractures in a patient with a unilateral hip fracture

Study Design

Enrollment

352 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: PENG Block Administration

Policy for the administration of the PENG block as per clinical guidelines to all subjects presenting to the hospital with a diagnosis of hip fracture and consenting to analgesic block

experimental: Femoral Block Administration

Policy for the administration of the Femoral block as per clinical guidelines to all subjects presenting to the hospital with a diagnosis of hip fracture and consenting to analgesic block

Interventions

PENG Block Administration

Policy for the PENG block administration:

30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg%

While these drugs are administered to participants, the intervention under evaluation is the PENG Block anesthesia technique.

Femoral Block Administration

Policy for the Femoral block administration:

30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg

While these drugs are administered to participants, the intervention under evaluation is the Femoral Block anesthesia technique.

Bupivacaine , epinephrine Dexamethasone

30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg%

Primary outcome measure

  • Mean Change in Numerical Rating Scale (NRS) Pain Score One Hour Post Block for all Subjects [ Time Frame: Baseline, 1-hour post block ]
  • Mean Change in Numerical Rating Scale (NRS) Pain Score One-Hour Post Block in Intracapsular Hip Fractures [ Time Frame: Baseline, 1-hour post block ]
  • Mean Change in Numerical Rating Scale (NRS) Pain Score One-Hour Post Block in Extracapsular Hip Fractures [ Time Frame: Baseline, 1-hour post block ]

Central Contacts and Locations

Central contacts

Michele Steinkamp, BSN, RN

212-746-2953mls9004@med.cornell.edu

Locations

Weill Cornell Medicine

Recruiting

Manhattan, New York, United States, 10065

Contacts

More Information

Sponsor

Weill Medical College of Cornell University

Last update posted

May 15, 2026

Last verified

May, 2026

Keywords

  • Pain
  • Anesthesia
  • Analgesia
  • Hip Fracture
  • Peripheral nerve block
  • Regional Anesthesia

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Weill Medical College of Cornell University on 2026-05-15.